For the quarter ending 2025-09-30, SNDX had $8,172K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -60,715 | -156,693 |
| Depreciation | 3 | 0 |
| Accretion of investments | 2,413 | 6,810 |
| Non-cash operating lease expense | 158 | 393 |
| Stock-based compensation | 12,082 | 24,167 |
| Amortization of debt issuance costs | 62 | 167 |
| Provision for credit losses | 3,667 | - |
| Accounts receivable | 5,949 | 11,852 |
| Inventory | 7,183 | 17,107 |
| Prepaid expenses and other assets | 4,364 | 4,778 |
| Collaboration (payable) receivable, net | -3,420 | -31,547 |
| Other receivable | 38 | -6 |
| Other assets | 0 | - |
| Accounts payable | -3,527 | 5,727 |
| Accrued expenses and other liabilities | 1,102 | 15,370 |
| Net cash used in operating activities | -70,535 | -182,957 |
| Purchases of property and equipment | 131 | - |
| Purchases of short and long-term investments | 30,440 | 102,251 |
| Proceeds from sales and maturities of short-term investments | 103,000 | 238,280 |
| Net cash provided by investing activities | 72,429 | 136,029 |
| Proceeds from employee stock purchase plan | -80 | 1,013 |
| Proceeds from stock option exercises | 6,358 | 468 |
| Net cash provided by financing activities | 6,278 | 1,481 |
| Net decrease cash, cash equivalents and restricted cash | 8,172 | -45,447 |
| Cash and cash equivalents at beginning of period | 154,300 | - |
| Cash and cash equivalents at end of period | 117,025 | - |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)